钛颗粒对OPG-RANKL-RANK通路干预的时间依赖性研究

目的 探讨钛颗粒在体外不同时间点对核因子-κB受体活化因子配体-核因子-κB受体活化因子-骨保护素(RANKL-RANK-OPG)通路的干预作用。 方法 MC3T3-E1细胞培养传5代后,移入4个6孔板中进行培养,随机分为A、B、C、D 4组,每板上3孔均加入含0.1mg/L钛颗粒培养液作为实验组,下3孔加入普通培养液作为对照组。A、B、C、D 4组分别在培养后12、24、36、48h提取培养液进行OPG和RANKL蛋白的ELISA检测,同时提取贴壁细胞进行real-time PCR检测,观察OPG和RANKL的mRNA表达水平变化。 结果 MC3T3-E1细胞连续传代后生长良好,形态稳定,经ELISA检测OPG蛋白吸光度(A)值A组10.33±2.44,B组8.96±2.02,C组7.84±1.30,D组7.66±0.63,B、C、D组与对照组相比,差异有统计学意义(P<0.05);RANKL蛋白A值A组6.04±1.60,B组7.51±0.57,C组8.91±0.59,D组10.94±0.58,4组与对照组相比,差异均有统计学意义(P<0.05)。经PCR检测OPG mRNA表达A组0.89±0.07,B组0.81±0.11,C组0.74±0.15,D组0.72±0.16,B、C、D组与对照组相比,差异有统计学意义(P<0.05);RANKL mRNA表达A组1.21±0.21,B组1.22±0.33,C组1.24±0.09,D组1.24±0.04,4组与对照组相比,差异均有统计学意义(P<0.05)。 结论 钛颗粒既能够上调RANKL的表达水平,又会抑制OPG的形成,从而加速假体周围的骨溶解作用。     

Clinical Unmet Needs and Treatment Patterns of Paediatric Psoriasis Patients: A Real-World Evidence Study in Spain

Background and objectiveReal-world evidence of paediatric psoriasis (PsO) is lacking in Spain. The purpose of this study was to identify physician-reported disease burden and current treatment patterns in a real-world paediatric PsO patient cohort in Spain. This will enhance our understanding of the disease and contribute to the development of regional guidelines.Material and methodThis retrospective analysis of a cross-sectional market research survey assessed the clinical unmet needs and treatment patterns in patients with paediatric PsO in Spain, as reported by their primary care and specialist physicians, using data collected as part of the Adelphi Real World Paediatric PsO Disease-Specific Program (DSP™) between February and October 2020.ResultsSurvey data from 57 treating physicians were included (71.9% [N = 41] dermatologists, 17.6% [N = 10] general practitioners/primary care physicians, and 10.5% [N = 6] paediatricians); the final analysis included 378 patients. At sampling, 84.1% (318/378) of patients had mild disease, 15.3% (58/378) had moderate disease and 0.5% (2/378) had severe disease. Retrospectively reported physician-judged severity at the time of PsO diagnosis recorded 41.8% (158/378) of patients with mild disease, 51.3% (194/378) with moderate disease and 6.9% (26/378) with severe disease. Overall, 89.3% (335/375) of patients were currently receiving topical PsO therapy, while 8.8% (33/375), 10.4% (39/375) and 14.9% (56/375) of patients were currently receiving phototherapy, conventional systemics and biologics, respectively.ConclusionsThese real-world data reflect the current burden and treatment landscape of paediatric PsO in Spain. The management of patients with paediatric PsO could be improved by further educating healthcare professionals and developing regional guidelines.     

[Artículo traducido] Necesidades clínicas no satisfechas y patrones de tratamiento de los pacientes pediátricos con psoriasis: estudio de evidencia en el mundo real en España

Background and objectiveReal-world evidence of paediatric psoriasis (PsO) is lacking in Spain. The purpose of this study was to identify physician-reported disease burden and current treatment patterns in a real-world paediatric PsO patient cohort in Spain. This will enhance our understanding of the disease and contribute to the development of regional guidelines.Material and methodThis retrospective analysis of a cross-sectional market research survey assessed the clinical unmet needs and treatment patterns in patients with paediatric PsO in Spain, as reported by their primary care and specialist physicians, using data collected as part of the Adelphi Real World Paediatric PsO Disease-Specific Program (DSP™) between February and October 2020.ResultsSurvey data from 57 treating physicians were included (71.9% [N = 41] dermatologists, 17.6% [N = 10] general practitioners/primary care physicians, and 10.5% [N = 6] paediatricians); the final analysis included 378 patients. At sampling, 84.1% (318/378) of patients had mild disease, 15.3% (58/378) had moderate disease and 0.5% (2/378) had severe disease. Retrospectively reported physician-judged severity at the time of PsO diagnosis recorded 41.8% (158/378) of patients with mild disease, 51.3% (194/378) with moderate disease and 6.9% (26/378) with severe disease. Overall, 89.3% (335/375) of patients were currently receiving topical PsO therapy, while 8.8% (33/375), 10.4% (39/375) and 14.9% (56/375) of patients were currently receiving phototherapy, conventional systemics and biologics, respectively.ConclusionsThese real-world data reflect the current burden and treatment landscape of paediatric PsO in Spain. The management of patients with paediatric PsO could be improved by further educating healthcare professionals and developing regional guidelines.